文献速递临床试验与 GCP医学人工智能与信息学

以患者为导向的电子决策支持工具(arriba-PPI)减少质子泵抑制剂长期使用:随机对照试验研究方案

Reduction of the long-term use of proton pump inhibitors by a patient-oriented electronic decision support tool (arriba-PPI): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-11-21

该研究为集群随机对照试验方案,在德国210家全科诊所和3150例患者中评估arriba-PPI电子决策支持工具能否减少质子泵抑制剂(PPI)长期使用。干预组全科医生使用该工具,对照组常规诊疗,观察6个月后比较每例患者PPI处方累积限定日剂量的减少情况。主要假设是干预可使PPI处方较常规策略减少至少15%。

要点

  • arriba-PPI是支持全科医生与患者共享决策的电子决策支持模块,用于减少PPI长期使用。
  • 试验计划纳入德国210家全科诊所和3150例长期服用PPI的患者,集群随机分组。
  • 主要比较指标为6个月内每例患者PPI处方累积限定日剂量的减少。

核心结论

  • 主要假设是应用arriba-PPI工具可使基层医疗中的PPI处方较全科医生常规策略减少至少15%。
  • 若结果阳性,意味着可将arriba-PPI工具纳入常规诊疗。

研究设计与样本

  • 集群随机对照试验,计划纳入德国210家全科诊所和3150例患者。
  • 每家诊所招募20例年龄≥18岁、规律服用PPI≥6个月的患者,招募完成后以诊所为单位进行集群随机分组。
  • 干预组全科诊所获得arriba-PPI软件使用权限,对照组全科医生按常规诊疗患者。
  • 观察6个月后比较两组每例患者PPI处方累积限定日剂量的减少情况。
  • 试验注册于德国临床试验注册库,注册号DRKS00016364,注册日期2019年1月31日。

关键数值与推荐

  • 主要结局为观察6个月后每例患者PPI处方累积限定日剂量的减少,两组进行比较。
  • 主要假设为arriba-PPI工具使PPI处方较全科医生常规策略减少至少15%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Proton pump inhibitors (PPIs) are increasingly being prescribed, although long-term use is associated with multiple side effects. Therefore, an electronic decision support tool with the aim of reducing the long-term use of PPIs in a shared decision-making process between general practitioners (GPs) and their patients has been developed. The developed tool is a module that can be added to the so-called arriba decision support tool, which is already used by GPs in Germany in routine care. In this large-scale cluster-randomized controlled trial we evaluate the effectiveness of this arriba-PPI tool. METHODS: The arriba-PPI tool is an electronic decision support system that supports shared decision-making and evidence-based decisions around the long-term use of PPIs at the point of care. The tool will be evaluated in a cluster-randomized controlled trial involving 210 GP practices and 3150 patients in Germany. GP practices will be asked to recruit 20 patients aged ≥ 18 years regularly taking PPIs for ≥ 6 months. After completion of patient recruitment, each GP practice with enrolled patients will be cluster-randomized. Intervention GP practices will get access to the software arriba-PPI, whereas control GPs will treat their patients as usual. After an observation period of six months, GP practices will be compared regarding the reduction of cumulated defined daily doses of PPI prescriptions per patient. DISCUSSION: Our principal hypothesis is that the application of the arriba-PPI tool can reduce PPI prescribing in primary care by at least 15% compared to conventional strategies used by GPs. A positive result implies the implementation of the arriba-PPI tool in routine care. TRIAL REGISTRATION: German Clinical Trials Register, DRKS00016364. Registered on 31 January 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Rieckert A, Becker A, Donner-Banzhof N, et al. Reduction of the long-term use of proton pump inhibitors by a patient-oriented electronic decision support tool (arriba-PPI): study protocol for a randomized controlled trial. Trials. 2019. PMID: 31752978. doi:10.1186/s13063-019-3728-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。